KYTX Stock Kyverna Therapeutics, Inc.

$4.26
1d-2.52%5d-15.64%1m-27.05%ytd-54.68%
At close · Nov 20, 4:00 PM ET
After hours $4.26 +0% · Nov 20, 6:11 PM ET
52w low $4.1751% of range$13.67 52w high
Price

Today’s call · KYTX

All live ideas →

6 of 6 technical checks lean bearish

KYTX is in a downtrend, momentum soft. $4.5 is the level overhead; $4 the first support below.

No open idea.From $4.26 the reward-to-risk to $4 against $4.5 is 1.1 — below the 3:1 bar.
What would create one:
  • A close below $4 on rising volume (breakdown).
  • A bounce to $4.5 that fails (entry near resistance).
Alert me at a level

The brief

Price vs 50-day · belowPrice vs 200-day · below50d vs 200d avg · belowMACD · bearishRSI momentum · 285-day tape · -15.6%
signalKYTX’s 50-day average is below the 200-day — long-term trend alignment is bearish.
momentumRSI 28.3 is oversold — the decline has been unusually fast.
volumeVolume is expanding vs its 20-day average.
newsKyverna Therapeutics, Inc. — Quarterly report (10-Q)
newsKyverna Therapeutics, Inc. — Form 8-K: 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
All readings
TrendDowntrend · below 50-day & below 200-day
MomentumRSI 28.3 · oversold · MACD bearish
Trend strengthADX 23.5 · developing
Location-27.8% vs 50-day MA
52-week range-62% from high · +0% from low
VolatilityATR 0.41 · ~9.6%/day
RSI 14
28.3
MACD
-0.43
ADX 14
23.5
ATR 14
0.41
SMA 50
$5.8969
SMA 200
$7.803

Levels that matter

$4.5round+5.6%
$5round+17.4%
$5.8969sma 50+38.4%
$4round−6.1%
$3.5round−17.8%
Next earnings: Nov 12Date, time & past reactions →

Compare with…

Analyst overview · Nov 15 · updated Nov 22

Kyverna Therapeutics (KYTX) stock analysis, November 15, 2026: bearish outlook, high conviction

Update, November 22, 2026

Since the November 15 report, KYTX slipped to $4.26, down 2.5% on the day and 15.6% over the past five days, while the S&P 500 fell 3.6% and the XLV health‑care ETF slipped 6.1% in the same period, keeping the stock’s under‑performance intact.

The picture holds: the daily close remains above the downside breakout threshold of $4.00, and the price is still trading below the key resistance at $4.50 where sellers have historically stepped in. The stop level of $4.60 (based on $4.50 plus a quarter of the 0.41 ATR) and the target at $3.50 remain unchanged. A weekly close above the swing‑zone at $7.22 would be required to alter the outlook.

Recent filings reinforce the bearish bias. The company’s Q3 2026 10‑Q disclosed a net loss of $41.9 million, a modest improvement year‑over‑year but still reflecting heavy cash burn, and an 8‑K announced the rolling BLA submission for miv‑cel in stiff‑person syndrome, seeking priority FDA review. SEC EDGAR provides the full details.

Kyverna Therapeutics (KYTX) closed at $5.05 on November 13, a modest 0.4% rise that left the shares well below the 40‑week average and still trailing the broader market. The daily price action follows a weekly downtrend, and the balance of evidence points to a bearish stance for the next two to six weeks. With a high conviction rating, the math suggests a downside breakout below $5.0 and a first target near the 52‑week low of $4.61.

Why it matters

The most recent price move came after the company reported earnings on November 12, which did not generate any notable headline. The stock’s 5‑day gain of 3.48% was modest compared with the S&P 500’s 2.59% rise and the healthcare sector ETF XLV’s 2.19% advance, indicating that the market’s reaction was driven more by the broader equity rally than by any specific catalyst for KYTX. The sector outperformance (XLV up 8.56% over the past month and 21.99% year‑to‑date) further underscores that the stock’s recent uptick is not a sector‑wide lift.

Long‑term fundamentals remain weak. The price sits below both the 50‑day simple moving average ($6.22) and the 200‑day average ($7.89), and the 14‑day RSI of 39 signals that the stock is approaching oversold territory but has not yet turned. The 52‑week range spans $11.25 to $4.61; at $5.05 the stock is 9.5% above the low, yet still 55% below the high, reflecting a prolonged decline from the recent peak of $6.21 on October 12, a drop of 18.7%.

Analyst sentiment is dramatically out of step with price. Five analysts rate the stock a strong buy, with a mean price target of $30.4, implying the market is trading at an 83.4% discount to that target. The consensus therefore reflects a valuation that is not yet reflected in the share price, but the technical picture and relative weakness versus SPY (‑17.6% over 50 days) and XLV (‑25.2% over 50 days) suggest that any upside from fundamentals will be delayed.

Debate in the community centers on whether the strong analyst consensus can overcome the technical downside. Proponents point to the large upside potential implied by the $30‑plus target, while detractors highlight the stock’s failure to hold above $6.0 on rallies and its alignment with a weekly downtrend. The evidence leans toward the latter, as sellers have consistently stepped in around the round $6.0 level, and the weekly close below the swing‑zone at $7.22 would be needed to reverse the trend.

What the evidence says

On the longer horizon the bearish thesis remains intact. The price is still below its 40‑week average, the weekly trend is down, and the stock continues to lag both the market and its sector. The recent 5‑day rally does not alter the structural weakness; the stock is still holding below the $6.0 round level that has acted as a ceiling on prior rallies.

Looking ahead to the next two to six weeks, the balance of evidence is negative with high conviction. The assessment notes that the daily trend runs with the weekly downtrend, the stock is lagging the S&P 500 by 17.6% over 50 days, and it is lagging XLV by 25.2% over the same period. These three points satisfy three of four conviction criteria, justifying a high‑conviction bearish stance. The strongest counter‑argument would be the analyst consensus of a strong‑buy rating and a mean target of $30.4, which suggests a massive upside. However, that view does not change the technical math: the stock would need to break well above $7.22 and sustain that level before the upside thesis gains traction, and the current price action shows no sign of such a move.

Levels that matter

The structure holds the stock below $6.0, a round level where sellers have repeatedly shown up on attempts to rally. The weekly trend would only end if a close above the swing‑zone at $7.22 occurs, a level that also serves as a resistance pivot.

The breakout math is clear: a downside breakout is defined by a daily close below the round $5.0 level. The stop is set at $6.11, calculated as $6.0 plus a quarter of the 14‑day ATR ($0.45). The first target is the 52‑week low at $4.61, offering a reward‑to‑risk of 0.4. Because the math does not achieve a 3‑to‑1 reward‑to‑risk ratio, the price would need to fall to roughly $4.00 for the trade to meet that threshold.

What would change the picture

A weekly close above the swing‑zone at $7.22 would alter the current downtrend narrative, signaling that buyers have regained control. The non‑price factor that could trigger such a shift would be a materially positive earnings surprise or a breakthrough in the company’s pipeline that convinces the market to reprice the stock.

What to watch

  • Next earnings on November 12 – focus on the earnings‑per‑share number and any guidance shift.
  • Sector catalysts: FDA approvals or major biotech M&A activity that could lift XLV and spill over to KYTX.
  • Valuation gap: the consensus strong‑buy rating with a mean target of $30.4, representing an 83% upside from the current price.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.